{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:06Z","timestamp":1791644766648,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the efficacy, safety, and tolerability of lifitegrast 5% versus carboxymethylcellulose (CMC) 0.5% in adult patients with dry eye disease (DED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 370 eligible patients with DED were randomized equally to receive twice-daily doses of a single drop in each eye of either lifitegrast 5% or CMC 0.5% for 12 weeks. Follow-up at weeks 2, 6, and 12 evaluated changes from baseline in primary [eye dryness score (EDS), ocular discomfort score (ODS), ocular surface disease index (OSDI), and tear film break-up time (TFBUT)] and secondary [Schirmer tear test (STT) score and corneal fluorescein staining (CFS) score] endpoints. Global improvement, safety, and tolerability were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At week 2, values of ocular discomfort score, OSDI, and conjunctival redness were significantly more favorable in patients treated with lifitegrast compared to CMC. At week 6, values of all study variables were better in patients treated with lifitegrast compared to CMC; differences between the groups were statistically significant for all except photophobia. This trend was also maintained at week 12. Global improvement and tolerability were found to be better with lifitegrast than with CMC. No serious safety concerns were reported in any treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>To our knowledge, this is the first active-controlled trial informing on the efficacy, safety, and tolerability of lifitegrast 5%. Significantly more favorable values for EDS (except photophobia), ODS, OSDI, TFBUT, STT score, CFS score, and conjunctival redness score were achieved at week 12 with lifitegrast 5% compared to CMC 0.5%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_23_24","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:00:08Z","timestamp":1723640408000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease"],"prefix":"10.4103","volume":"73","author":[{"given":"Namrata","family":"Sharma","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Basu","sequence":"additional","affiliation":[{"name":"LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shetty","sequence":"additional","affiliation":[{"name":"Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Kumar","sequence":"additional","affiliation":[{"name":"King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Mondal","sequence":"additional","affiliation":[{"name":"Regional Institute of Ophthalmology, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Seshu","family":"Babu","sequence":"additional","affiliation":[{"name":"Government Medical College and Government General Hospital, (Old RIMS), Srikakulam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Vatsalya Multispeciality Hospital, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana A","family":"Pande","sequence":"additional","affiliation":[{"name":"B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubashree","family":"Karat","sequence":"additional","affiliation":[{"name":"St. John\u2019s Medical College and Hospital, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemaxi P","family":"Desai","sequence":"additional","affiliation":[{"name":"GCS Medical College, Hospital and Research Centre, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Manjula","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Krishna","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"R1-20260424","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: A Bayesian view","volume":"41","author":"Papas","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"key":"R3-20260424","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4103\/ijo.IJO_2299_19","article-title":"Dry eye disease in India","volume":"68","author":"Chatterjee","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R4-20260424","first-page":"1","article-title":"Dry eye disease: A comprehensive review","volume":"2","author":"Dahal","year":"2020","journal-title":"Integr J Conf Proc"},{"key":"R5-20260424","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arzteblatt Int"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/OPTH.S281666","article-title":"Trends in dry eye disease management worldwide","volume":"15","author":"Hantera","year":"2021","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"e000697","DOI":"10.1136\/bmjophth-2020-000697","article-title":"Dry eye: Why artificial tears are not always the answer","volume":"6","author":"Kim","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/OPTH.S347496","article-title":"Reduction of artificial tears and use of adjunctive dry eye therapies after lifitegrast treatment: Evidence from clinical and real-world studies","volume":"16","author":"Nichols","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ICL.0000000000000020","article-title":"Perceptions of dry eye disease management in current clinical practice","volume":"40","author":"Williamson","year":"2014","journal-title":"Eye Contact Lens"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Overview of clinical trial program","volume":"22","author":"Chan","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/OPTH.S347496","article-title":"Reduction of artificial tears and use of adjunctive dry eye therapies after lifitegrast treatment: Evidence from clinical and real-world studies","volume":"16","author":"Nichols","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14656566.2017.1372748","article-title":"Lifitegrast for the treatment of dry eye disease in adults","volume":"18","author":"Donnenfeld","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: Results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: Results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: A 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"key":"R19-20260424","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Overview of clinical trial program","volume":"22","author":"Chan","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/ijo.IJO_698_17","article-title":"Prevalence and risk factors of dry eye disease in North India: Ocular surface disease index-based cross-sectional hospital study","volume":"66","author":"Titiyal","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R21-20260424","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: Results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: Results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/meajo.MEAJO_165_15","article-title":"Comparison of the efficacy of carboxymethylcellulose 0.5%, hydroxypropyl-guar containing polyethylene glycol 400\/propylene glycol, and hydroxypropyl methyl cellulose 0.3% tear substitutes in improving ocular surface disease index in cases of dry eye","volume":"24","author":"Maharana","year":"2017","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R25-20260424","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2147\/OPTH.S161578","article-title":"Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis","volume":"12","author":"Gro\u00df","year":"2018","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R26-20260424","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ICO.0b013e3181e9adcc","article-title":"Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease","volume":"30","author":"Lee","year":"2011","journal-title":"Cornea"},{"key":"R27-20260424","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine a solution for treatment of dry eye disease: Results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"R28-20260424","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clae.2018.12.003","article-title":"Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study","volume":"42","author":"Lievens","year":"2019","journal-title":"Contact Lens Anterior Eye"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_23_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:01:51Z","timestamp":1787839311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_23_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_23_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"2024-01-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}